Skip to main content

Validation of a high resolution NGS method for detecting spinal muscular atrophy carriers among phase 3 participants in the 1000 Genomes Project

Author(s): Larson, Jessica L; Silver, Ari J; Chan, Dalin; Borroto, Carlos; Spurrier, Brett; et al

Download
To refer to this page use: http://arks.princeton.edu/ark:/88435/pr1tq5rd16
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLarson, Jessica L-
dc.contributor.authorSilver, Ari J-
dc.contributor.authorChan, Dalin-
dc.contributor.authorBorroto, Carlos-
dc.contributor.authorSpurrier, Brett-
dc.contributor.authorSilver, Lee M-
dc.date.accessioned2022-01-25T14:52:03Z-
dc.date.available2022-01-25T14:52:03Z-
dc.date.issued2015-12en_US
dc.identifier.citationLarson, Jessica L, Silver, Ari J, Chan, Dalin, Borroto, Carlos, Spurrier, Brett, Silver, Lee M. (2015). Validation of a high resolution NGS method for detecting spinal muscular atrophy carriers among phase 3 participants in the 1000 Genomes Project. BMC Medical Genetics, 16 (1), 10.1186/s12881-015-0246-2en_US
dc.identifier.urihttp://arks.princeton.edu/ark:/88435/pr1tq5rd16-
dc.description.abstractSpinal muscular atrophy (SMA) is the most common pan-ethnic cause of early childhood death due to mutations in a single gene, SMN1. Most chromosome 5 homologs have a functional gene and dysfunctional copy, SMN2, with a single synonymous base substitution that results in faulty RNA splicing. However, the copy number of SMN1 and SMN2 is highly variable, and one in 60 adults worldwide are SMA carriers. Although population-wide screening is recommended, current SMA carrier tests have not been incorporated into targeted gene panels. Here we describe a novel computational protocol for determining SMA carrier status based solely on individual exome data. Our method utilizes a Bayesian hierarchical model to quantify an individual’s carrier probability given only his or her SMN1 and SMN2 reads at six loci of interest. We find complete concordance with results obtained with the current qPCR-based testing standard in known SMA carriers and affecteds. We applied our protocol to the phase 3 cohort of the 1,000 Genomes Project and found carrier frequencies in multiple populations consistent with the present literature. Our process is a convenient, robust alternative to qPCR, which can easily be integrated into the analysis of large multi-gene NGS carrier screens.en_US
dc.language.isoen_USen_US
dc.relation.ispartofBMC Medical Geneticsen_US
dc.rightsFinal published version. This is an open access article.en_US
dc.titleValidation of a high resolution NGS method for detecting spinal muscular atrophy carriers among phase 3 participants in the 1000 Genomes Projecten_US
dc.typeJournal Articleen_US
dc.identifier.doidoi:10.1186/s12881-015-0246-2-
dc.date.eissued2015-10-29en_US
dc.identifier.eissn1471-2350-
pu.type.symplectichttp://www.symplectic.co.uk/publications/atom-terms/1.0/journal-articleen_US

Files in This Item:
File Description SizeFormat 
validation_high_resolution_atrophy_1000_genomes_project.pdf1.22 MBAdobe PDFView/Download


Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.